Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Kronos Bio, Inc. (KRON)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.85+0.17 (+1.46%)
At close: 04:00PM EST
11.85 0.00 (0.00%)
After hours: 06:03PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.68
Open11.82
Bid11.82 x 1000
Ask35.00 x 1100
Day's Range11.49 - 12.12
52 Week Range11.03 - 38.98
Volume179,741
Avg. Volume233,377
Market Cap664.428M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est42.25
  • GlobeNewswire

    Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742

    Initial data demonstrate long plasma half-life and dose-dependent target inhibition Trial is continuing to enroll patients on three-day on, four-day off schedule SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced positive data from the ongoing Phase 1/2 clinical trial of KB-0742, the company’s internally discovered, highly selective, oral cyclin depen

  • GlobeNewswire

    Kronos Bio Announces Participation in Upcoming Investor Conferences

    SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: Piper Sandler’s 33rd Annual Virtual Healthcare Conference on Tuesday, November 30, 2021 at 11 a.m. Eastern Time; andEvercore ISI’s 4th Annual HealthCONx on Thursday, December 2, 2021 at 1 p.m.

  • GlobeNewswire

    Kronos Bio Appoints Roshawn Blunt to Board of Directors

    SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Roshawn Blunt to the company’s Board of Directors. Ms. Blunt has more than 25 years of experience in the biopharmaceutical and medical device industries. She founded and currently is managing director of 1798, LLC, a national health care consulting firm. She began her pharmaceutical

Advertisement
Advertisement